MDACC Study No:2006-0472 ( NCT No: NCT00671801)
Title:Phase I/II Trial of Irinotecan plus Lenalidomide in Adult Patients with Recurrent Glioblastoma Multiforme
Principal Investigator:John DeGroot
Treatment Agent:Irinotecan; Lenalidomide
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of lenalidomide combined with Camptosar (irinotecan) as well as to see if this
drug combination can help control malignant gliomas.

Researchers will also study if a special magnetic resonance imaging (MRI)
technique (dynamic MRI scan) is useful in looking at the effect of treatment on
the tumor. Another goal is to learn the effect of lenalidomide on tumor tissue
in patients who need surgery for the disease.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I/Phase II
Treatment Agents:Irinotecan
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:every 2 weeks
Home Care:Lenalidomide is oral drug that may be and taken at home

Hide details for Study Contact InformationStudy Contact Information

Physician Name:John DeGroot
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults